Hims & Hers Health Reports Better-Than-Expected Q1 Results, Strong Guidance
Hims & Hers Health reported quarterly GAAP earnings of 5 cents per share which beat the analyst consensus estimate of 2 cents by 150%.
BioCryst Pharmaceuticals ‘Fantastic’ Q1 Earnings Rides On Outstanding Orladeyo Performance
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NMIBC patients and TAR-200's promising outcomes for BCG-unresponsive cases.
Hormel Foods Recalls Some Contaminated Planters Nuts In Five States
Hormel Foods recalls Planters products due to listeria contamination. Details on impacted items & distribution areas.
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Why Is Medical Device Maker Integra LifeSciences Stock Falling On Monday?
Integra LifeSciences surpasses expectations with first-quarter revenues of $368.9 million, reporting growth in Codman Specialty Surgical and updates fiscal year 2024 guidance.
What’s Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves.
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
‘Ozempic Ftw:’ Elon Musk Touts Novo Nordisk’s Blockbuster Drug As Solution To Childhood Obesity Problem
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart.
Genomics firm Twist Bioscience’s Momentum To Continue Throughout 2024, Analyst Says
Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.